Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

925.81 +18.95 (+2.09%)
Official Closing Price Updated: 6:30 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now
Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy. 
Via The Motley Fool
Microsoft Gets $135 Billion OpenAI Stake
Via The Motley Fool
The Resilient Market: Investor Optimism and the Enduring Power of "Dip-Buying" in November 2025
As November 2025 unfolds, the financial markets are characterized by a palpable sense of cautious optimism, a sentiment largely underpinned by the continued prevalence and success of "dip-buying"... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs
Via Stocktwits
Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Rise
Via Stocktwits
The Shifting Sands of Valuation: Understanding Market Cap Movers in a Dynamic Market
In the intricate tapestry of global financial markets, few metrics hold as much sway and immediate relevance as market capitalization. Representing the total dollar value of a company's outstanding... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Earnings
Tech Titans and Pharma Powerhouses Drive Market Volatility: AMD, Palantir, Micron, and Eli Lilly in Focus
As of November 5, 2025, the financial markets experienced a day of notable activity, with several key players across the technology and pharmaceutical sectors capturing investor attention. Advanced... 
Via MarketMinute
Topics Artificial Intelligence Economy
Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars
The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo... 
Via MarketMinute
Topics Economy
Market Recovers from Tariff Turmoil: Dow, S&P 500, and Nasdaq Stage Resilient Rebound Amid Shifting Economic Winds
The U.S. financial markets have demonstrated remarkable resilience in 2025, staging a significant rebound after experiencing a sharp selloff earlier in the year. The Dow Jones Industrial Average, S&P... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing... 
Via Benzinga
Topics Economy
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides
In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week... 
Via MarketMinute
Topics Economy Intellectual Property Supply Chain
Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain
Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross. 
Via Benzinga
Jim Cramer Says 'Take A Pass' On This Tech Stock, Won't Go Near Oils
Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profrac and Altria. 
Via Benzinga
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development. 
Via The Motley Fool
Eli Lilly And Company Stock Signal: Did Earnings Justify The Rally?
A massive earnings beat sent shares rallying, but the latest GLP-1 treatment underperformed, while long-term debt is rising and profit margins are shrinking. 
Via Talk Markets
Topics Earnings
Elanco (NYSE:ELAN) Surprises With Q3 Sales
Animal health company Elanco (NYSE:ELAN) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 10.4% year on year to $1.14 billion. Guidance for next quarter’s revenue was... 
Via StockStory
This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?
Lilly's GLP-1 drug became the best-selling drug on Earth in the third quarter. 
Via The Motley Fool
Can Novo Nordisk’s ‘Attractive’ Fundamentals Outweigh Slowing Wegovy Sales And A $149 Price Cap?
Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins. 
Via Stocktwits
Topics Lawsuit
Eli Lilly Stock Sees RS Rating Rise To 77
li Lilly stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 70 to 77. 
Via Investor's Business Daily
Earnings To Watch: Collegium Pharmaceutical (COLL) Reports Q3 Results Tomorrow
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors should know. 
Via StockStory
Viatris (VTRS) Q3 Earnings Report Preview: What To Look For
Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets.
It's a great idea to watch the latest moves of this expert investor. 
Via The Motley Fool
Topics Artificial Intelligence
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
Via TokenRing AI
Topics Artificial Intelligence
Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play
Via MarketBeat
Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House
Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports indicating the company is close to finalizing a White House agreement to provide... 
Via Benzinga
Is Eli Lilly a Millionaire Maker?
Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider. 
Via The Motley Fool
Topics Intellectual Property
Are Wall Street Analysts Predicting Eli Lilly Stock Will Climb or Sink?
While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects. 
Via Barchart.com
Elanco (ELAN) To Report Earnings Tomorrow: Here Is What To Expect
Animal health company Elanco (NYSE:ELAN) will be reporting earnings this Wednesday before market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.